United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,235 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $130.49, for a total transaction of $161,155.15. Following the sale, the chief executive officer now directly owns 2,304 shares of the company’s stock, valued at approximately $300,648.96. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

United Therapeutics Corporation (NASDAQ UTHR) traded up 1.95% during trading on Friday, hitting $133.35. The stock had a trading volume of 508,729 shares. The company’s 50-day moving average is $130.07 and its 200 day moving average is $132.13. The firm has a market cap of $5.79 billion, a PE ratio of 15.46 and a beta of 1.51. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same period in the previous year, the business posted $4.42 EPS. United Therapeutics Corporation’s revenue for the quarter was up 7.8% compared to the same quarter last year. Equities analysts expect that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Martine A. Rothblatt Sells 1,235 Shares of United Therapeutics Corporation (UTHR) Stock” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/01/martine-a-rothblatt-sells-1235-shares-of-united-therapeutics-corporation-uthr-stock.html.

A number of hedge funds have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new position in shares of United Therapeutics Corporation during the second quarter valued at about $285,000. Ameritas Investment Partners Inc. increased its position in shares of United Therapeutics Corporation by 1.7% in the second quarter. Ameritas Investment Partners Inc. now owns 13,485 shares of the biotechnology company’s stock valued at $1,749,000 after buying an additional 231 shares during the last quarter. Nomura Holdings Inc. acquired a new position in shares of United Therapeutics Corporation during the second quarter valued at about $403,000. The Manufacturers Life Insurance Company increased its position in shares of United Therapeutics Corporation by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 66,372 shares of the biotechnology company’s stock valued at $8,611,000 after buying an additional 1,242 shares during the last quarter. Finally, Caxton Associates LP increased its position in shares of United Therapeutics Corporation by 27.3% in the second quarter. Caxton Associates LP now owns 2,800 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 600 shares during the last quarter.

UTHR has been the subject of a number of research analyst reports. ValuEngine raised shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. BidaskClub cut United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. UBS AG restated a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Finally, Jefferies Group LLC restated a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a report on Friday, July 14th. Six investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $134.50.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.